Zhongyu Liu

Economical, Practical, and Scalable Synthetic Process Development for the Antiglaucoma Drug Omidenepag Isopropyl

Abstract Omidenepag isopropyl (OMDI) is the only marketed antiglaucoma drug that acts as a prostaglandin E receptor 2 (EP2) agonist. It exhibits high receptor-binding affinity (Ki = 3.6 nM) and potent agonistic activity (EC50 = 8.3 nM). More importantly, OMDI circumvents key limi...